ISOTYPES OF ANTI-PERTUSSIS ANTIBODIES IN PERTUSSIS PATIENTS AT DIFFERENT STAGES OF THE DISEASE


Cite item

Full Text

Abstract

Aim. Evaluation of anti-pertussis antibodies in pertussis patients at different stages after the onset of the disease. Materials and methods. Levels of IgG, IgG1, IgG2, IgG3, IgG4, IgA and IgM antibodies against the antigen complex of pertussis were evaluated by enzyme immunoassay (EIA). Sera samples were analyzed from 208 pertussis patients examined from week 1 to 10 after the onset of the disease. Results. 51%, 82% and 86% pertussis patients, and 67%, 72% and 78% patients examined from week 1 to 3 after the onset of the disease had increased levels of IgM, IgA and IgG antibodies respectively. 85%, 70%, 74% and 68% pertussis patients, and 76%, 57%, 87%, 57% patients examined from week 1 to 3 after the onset of the disease had increased IgG1, IgG2, IgG3 and IgG4 levels respectively. 92% of all examined pertussis patients and 83% of patients examined from week 1 to 3 after the onset of the disease had an overall increase of anti-pertussis antibody levels. Increased level of IgM antibodies was detected predominately from week 1 to 5 after the onset of the disease. Most of the patients examined from week 3 to 10 after the onset of the disease had increased levels of IgA, IgG, IgG1, IgG2 and IgG4 antibodies, and IgG3 antibody level was increased predominately in patients examined from week 2 to 6 after the onset of the disease. Conclusion. Serological indicators of pertussis measured by EIA were observed in 83% of the patients examined at the early stages after the onset of the disease. Simultaneous measure- ment of IgA, IgG and IgM antibody levels is the most effective approach for serological diagnostics of pertussis due anti-pertussis antibodies isotype composition heterogeneity at different stages after the onset of the disease. Increased levels of IgM and IgG3 antibodies are serologic indicators of the acute phase of pertussis infection.

Full Text

ИЗОТИПЫ ПРОТИВОКОКЛЮШНЫХ АНТИТЕЛ У БОЛЬНЫХ КОКЛЮШЕМ НА РАЗНЫХ СРОКАХ ЗАБОЛЕВАНИЯ
×

About the authors

E. M Zaytsev

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

L. I Krasnoproshina

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

I. K Mazurova

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Moscow, Russia

M. S Petrova

Clinical Infectious Diseases Hospital No. 1, Moscow, Russia

O. P Popova

Clinical Infectious Diseases Hospital No. 1, Moscow, Russia

N. S Zakharova

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

References

  1. Зайцев Е.М., Мазурова И.К., Петрова М.С. и др. Диагностическое значение IgG, IgA и IgM антител к различным антигенам Bordetella pertussis у больных коклюшем. Журн. микробиол. 2008, 6: 23-26.
  2. Зайцев Е.М., Мазурова И.К., Петрова М.С. и др. Распределение подклассов специфических IgG у больных коклюшем и здоровых людей. Там же. 2009, 2: 57-61.
  3. Тимченко В.Н., Бабаченко И.В., Ценева Г.Я. Эволюция коклюшной инфекции у детей. Санкт-Петербург, ЭЛБИ-СПб, 2005.
  4. Leung A.K., Robson W.L., Davies H.D. Pertussis in adolescents. Adv.Ther. 2007, 24 (2): 353-361.
  5. Mertens P.L., Stals F.S., Steyerberg E.W. et al. Setnsitivity and specificity of single IgA and IgG antibody concentrations for early diagnosis of pertussis in adults: an evaluation for outbreak management in public health practice. BMC Infect. Dis. 2007, 7: 53.
  6. Mertsola J. Whooping cough. Serological and epidemiological studies. Turku, Finland, 1985, 47-48.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2011 Zaytsev E.M., Krasnoproshina L.I., Mazurova I.K., Petrova M.S., Popova O.P., Zakharova N.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies